annual CFF:
$870.52M+$617.47M(+244.01%)Summary
- As of today (June 22, 2025), ARWR annual cash flow from financing activities is $870.52 million, with the most recent change of +$617.47 million (+244.01%) on September 30, 2024.
- During the last 3 years, ARWR annual CFF has risen by +$859.22 million (+7600.31%).
- ARWR annual CFF is now at all-time high.
Performance
ARWR Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$92.38M+$71.75M(+347.72%)Summary
- As of today (June 22, 2025), ARWR quarterly cash flow from financing activities is $92.38 million, with the most recent change of +$71.75 million (+347.72%) on March 31, 2025.
- Over the past year, ARWR quarterly CFF has dropped by -$338.39 million (-78.55%).
- ARWR quarterly CFF is now -78.55% below its all-time high of $430.78 million, reached on March 31, 2024.
Performance
ARWR quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$552.49M-$338.39M(-37.98%)Summary
- As of today (June 22, 2025), ARWR TTM cash flow from financing activities is $552.49 million, with the most recent change of -$338.39 million (-37.98%) on March 31, 2025.
- Over the past year, ARWR TTM CFF has increased by +$119.49 million (+27.60%).
- ARWR TTM CFF is now -37.98% below its all-time high of $890.89 million, reached on December 31, 2024.
Performance
ARWR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ARWR Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +244.0% | -78.5% | +27.6% |
| 3 y3 years | +7600.3% | +4904.4% | +7467.4% |
| 5 y5 years | +1211.4% | +6830.4% | +113.0% |
ARWR Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +7600.3% | -78.5% | >+9999.0% | -38.0% | >+9999.0% |
| 5 y | 5-year | at high | +7600.3% | -78.5% | >+9999.0% | -38.0% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -78.5% | >+9999.0% | -38.0% | >+9999.0% |
ARWR Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $92.38M(+347.7%) | $552.49M(-38.0%) |
| Dec 2024 | - | $20.63M(-94.7%) | $890.89M(+2.3%) |
| Sep 2024 | $870.52M(+244.0%) | $389.09M(+672.2%) | $870.52M(+80.5%) |
| Jun 2024 | - | $50.39M(-88.3%) | $482.25M(+11.4%) |
| Mar 2024 | - | $430.78M(>+9900.0%) | $433.00M(>+9900.0%) |
| Dec 2023 | - | $267.00K(-67.5%) | $2.74M(-98.9%) |
| Sep 2023 | $253.05M(+288.2%) | $821.00K(-27.7%) | $253.05M(-0.0%) |
| Jun 2023 | - | $1.14M(+118.5%) | $253.09M(-19.0%) |
| Mar 2023 | - | $520.00K(-99.8%) | $312.55M(-0.4%) |
| Dec 2022 | - | $250.58M(>+9900.0%) | $313.88M(+381.5%) |
| Sep 2022 | $65.19M(+476.6%) | $855.00K(-98.6%) | $65.19M(+0.1%) |
| Jun 2022 | - | $60.60M(+3182.8%) | $65.15M(+792.3%) |
| Mar 2022 | - | $1.85M(-2.1%) | $7.30M(-9.7%) |
| Dec 2021 | - | $1.89M(+131.3%) | $8.09M(-28.5%) |
| Sep 2021 | $11.30M(-95.6%) | $815.00K(-70.4%) | $11.30M(-1.7%) |
| Jun 2021 | - | $2.75M(+4.6%) | $11.49M(+5.7%) |
| Mar 2021 | - | $2.63M(-48.4%) | $10.87M(+13.6%) |
| Dec 2020 | - | $5.10M(+407.7%) | $9.57M(-96.3%) |
| Sep 2020 | $257.95M(+288.6%) | $1.00M(-52.9%) | $257.95M(-0.3%) |
| Jun 2020 | - | $2.13M(+59.9%) | $258.78M(-0.2%) |
| Mar 2020 | - | $1.33M(-99.5%) | $259.41M(-0.5%) |
| Dec 2019 | - | $253.48M(>+9900.0%) | $260.75M(+292.8%) |
| Sep 2019 | $66.38M(+10.7%) | $1.83M(-33.7%) | $66.38M(+0.4%) |
| Jun 2019 | - | $2.77M(+3.6%) | $66.12M(+2.0%) |
| Mar 2019 | - | $2.67M(-95.5%) | $64.81M(-45.6%) |
| Dec 2018 | - | $59.11M(+3662.4%) | $119.04M(+98.6%) |
| Sep 2018 | $59.95M(+397.3%) | $1.57M(+8.0%) | $59.95M(+2.9%) |
| Jun 2018 | - | $1.45M(-97.4%) | $58.26M(+2.6%) |
| Mar 2018 | - | $56.90M(>+9900.0%) | $56.81M(>+9900.0%) |
| Dec 2017 | - | $26.30K(-121.5%) | $46.10K(-99.6%) |
| Sep 2017 | $12.06M(-78.1%) | -$122.30K(<-9900.0%) | $12.06M(-81.7%) |
| Jun 2017 | - | $0.00(-100.0%) | $65.82M(-3.2%) |
| Mar 2017 | - | $142.10K(-98.8%) | $68.03M(+0.5%) |
| Dec 2016 | - | $12.04M(-77.6%) | $67.66M(+22.7%) |
| Sep 2016 | $55.13M(>+9900.0%) | $53.64M(+2332.8%) | $55.13M(+3292.9%) |
| Jun 2016 | - | $2.21M(-1091.5%) | $1.62M(-356.5%) |
| Mar 2016 | - | -$222.40K(-55.0%) | -$633.60K(+64.8%) |
| Dec 2015 | - | -$494.60K(-461.3%) | -$384.40K(-232.3%) |
| Sep 2015 | $290.50K(-99.8%) | $136.90K(-355.9%) | $290.50K(-57.9%) |
| Jun 2015 | - | -$53.50K(-299.6%) | $689.40K(-86.4%) |
| Mar 2015 | - | $26.80K(-85.1%) | $5.08M(-95.9%) |
| Dec 2014 | - | $180.30K(-66.3%) | $122.71M(-33.8%) |
| Sep 2014 | $185.29M(+318.4%) | $535.80K(-87.7%) | $185.29M(-0.8%) |
| Jun 2014 | - | $4.34M(-96.3%) | $186.76M(-14.2%) |
| Mar 2014 | - | $117.65M(+87.4%) | $217.73M(+109.8%) |
| Dec 2013 | - | $62.77M(+3033.8%) | $103.78M(+134.3%) |
| Sep 2013 | $44.29M(+311.3%) | $2.00M(-94.3%) | $44.29M(-7.3%) |
| Jun 2013 | - | $35.31M(+853.3%) | $47.79M(+215.7%) |
| Mar 2013 | - | $3.70M(+12.9%) | $15.14M(+20.0%) |
| Dec 2012 | - | $3.28M(-40.4%) | $12.62M(+17.2%) |
| Sep 2012 | $10.77M | $5.50M(+107.5%) | $10.77M(+10.8%) |
| Jun 2012 | - | $2.65M(+124.7%) | $9.72M(+37.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $1.18M(-17.5%) | $7.08M(-7.1%) |
| Dec 2011 | - | $1.43M(-67.8%) | $7.62M(+22.3%) |
| Sep 2011 | $6.23M(-48.3%) | $4.45M(>+9900.0%) | $6.23M(+197.1%) |
| Jun 2011 | - | $13.90K(-99.2%) | $2.10M(-79.6%) |
| Mar 2011 | - | $1.72M(+3870.4%) | $10.25M(+12.8%) |
| Dec 2010 | - | $43.30K(-86.4%) | $9.09M(-24.5%) |
| Sep 2010 | $12.04M(+86.2%) | $319.10K(-96.1%) | $12.04M(-15.6%) |
| Jun 2010 | - | $8.17M(+1363.6%) | $14.27M(+142.0%) |
| Mar 2010 | - | $558.10K(-81.4%) | $5.90M(+0.1%) |
| Dec 2009 | - | $2.99M(+17.4%) | $5.89M(-8.9%) |
| Sep 2009 | $6.46M(-59.9%) | $2.55M(-1346.5%) | $6.46M(-67.3%) |
| Jun 2009 | - | -$204.60K(-137.2%) | $19.76M(-1.0%) |
| Mar 2009 | - | $549.40K(-84.6%) | $19.96M(+2.8%) |
| Dec 2008 | - | $3.57M(-77.5%) | $19.41M(+20.3%) |
| Sep 2008 | $16.13M(+3.5%) | $15.84M(>+9900.0%) | $16.13M(+5161.9%) |
| Jun 2008 | - | $0.00(0.0%) | $306.60K(-98.0%) |
| Mar 2008 | - | $0.00(-100.0%) | $15.56M(-0.0%) |
| Dec 2007 | - | $290.00K(+1647.0%) | $15.56M(-0.2%) |
| Sep 2007 | $15.59M(-25.4%) | $16.60K(-99.9%) | $15.59M(-7.6%) |
| Jun 2007 | - | $15.25M(>+9900.0%) | $16.87M(+917.9%) |
| Mar 2007 | - | $4000.00(-98.7%) | $1.66M(-92.2%) |
| Dec 2006 | - | $316.20K(-75.8%) | $21.20M(+1.5%) |
| Sep 2006 | $20.89M(+0.7%) | $1.30M(+3792.8%) | $20.89M(+6.5%) |
| Jun 2006 | - | $33.50K(-99.8%) | $19.62M(-49.1%) |
| Mar 2006 | - | $19.55M(>+9900.0%) | $38.54M(+88.1%) |
| Dec 2005 | - | $4000.00(-89.4%) | $20.48M(-1.3%) |
| Sep 2005 | $20.74M(+110.1%) | $37.60K(-99.8%) | $20.74M(+0.9%) |
| Jun 2005 | - | $18.95M(+1169.4%) | $20.56M(+1014.1%) |
| Mar 2005 | - | $1.49M(+465.2%) | $1.85M(-81.1%) |
| Dec 2004 | - | $264.10K(-284.3%) | $9.74M(-1.3%) |
| Sep 2004 | $9.87M(+551.6%) | -$143.30K(-161.7%) | $9.87M(-14.0%) |
| Jun 2004 | - | $232.10K(-97.5%) | $11.48M(+2.0%) |
| Mar 2004 | - | $9.39M(+2286.0%) | $11.26M(+490.5%) |
| Dec 2003 | - | $393.50K(-73.2%) | $1.91M(+25.9%) |
| Sep 2003 | $1.51M(+1105.3%) | $1.47M(>+9900.0%) | $1.51M(+6346.4%) |
| Jun 2003 | - | $12.10K(-64.7%) | $23.50K(-79.4%) |
| Mar 2003 | - | $34.30K(+2538.5%) | $114.30K(+16.2%) |
| Dec 2002 | - | $1300.00(-105.4%) | $98.40K(-21.7%) |
| Sep 2002 | $125.70K(+56.9%) | -$24.20K(-123.5%) | $125.70K(-23.3%) |
| Jun 2002 | - | $102.90K(+459.2%) | $163.90K(+112.6%) |
| Mar 2002 | - | $18.40K(-35.7%) | $77.10K(-15.8%) |
| Dec 2001 | - | $28.60K(+104.3%) | $91.60K(+14.2%) |
| Sep 2001 | $80.10K(-3.1%) | $14.00K(-13.0%) | $80.20K(-9.6%) |
| Jun 2001 | - | $16.10K(-51.1%) | $88.70K(-33.7%) |
| Mar 2001 | - | $32.90K(+91.3%) | $133.80K(+33.3%) |
| Dec 2000 | - | $17.20K(-23.6%) | $100.40K(+21.4%) |
| Sep 2000 | $82.70K(+141.1%) | $22.50K(-63.2%) | $82.70K(+37.4%) |
| Jun 2000 | - | $61.20K(<-9900.0%) | $60.20K(-6120.0%) |
| Mar 2000 | - | -$500.00(0.0%) | -$1000.00(+100.0%) |
| Dec 1999 | - | -$500.00 | -$500.00 |
| Sep 1999 | $34.30K(<-9900.0%) | - | - |
| Sep 1998 | -$200.00(-95.5%) | - | - |
| Sep 1997 | -$4400.00 | - | - |
FAQ
- What is Arrowhead Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual CFF year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly CFF year-on-year change?
- What is Arrowhead Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals TTM CFF year-on-year change?
What is Arrowhead Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of ARWR is $870.52M
What is the all time high annual CFF for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual cash flow from financing activities is $870.52M
What is Arrowhead Pharmaceuticals annual CFF year-on-year change?
Over the past year, ARWR annual cash flow from financing activities has changed by +$617.47M (+244.01%)
What is Arrowhead Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of ARWR is $92.38M
What is the all time high quarterly CFF for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly cash flow from financing activities is $430.78M
What is Arrowhead Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, ARWR quarterly cash flow from financing activities has changed by -$338.39M (-78.55%)
What is Arrowhead Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of ARWR is $552.49M
What is the all time high TTM CFF for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high TTM cash flow from financing activities is $890.89M
What is Arrowhead Pharmaceuticals TTM CFF year-on-year change?
Over the past year, ARWR TTM cash flow from financing activities has changed by +$119.49M (+27.60%)